ethyl eicosapentaenoic acid eepa icosapent ethyl sold brand name vascepa among others medication used treat used combination changes diet adults hypertriglyceridemia mgdl often required used statin maximallytolerated common side effects musculoskeletal pain peripheral edema swelling legs hands atrial fibrillation arthralgia joint common side effects include bleeding constipation gout made fatty acid eicosapentaenoic acid us food drug administration fda granted approval icosapent ethyl amarin corporation became second fish oilbased medication ethyl esters brand named lovaza approved december fda also approved vascepa first drug specifically reduce cardiovascular risk among people elevated triglyceride available generic commonly prescribed medication united states million european union icosapent ethyl indicated reduce cardiovascular risk adjunct statin united states icosapent ethyl indicated adjunct maximally tolerated statin therapy reduce risk myocardial infarction stroke coronary revascularization unstable angina requiring hospitalization adults elevated triglyceride levels mgdl established cardiovascular disease diabetes two additional risk factors cardiovascular also indicated adjunct diet reduce triglyceride levels adults severe mgdl intake large doses gday longchain fatty acids prescription drugs dietary supplements generally required achieve significant lowering triglycerides doses effects significant even individuals levels greater mgdlmedical citation needed appears eicosapentaenoic acid epa docosahexaenoic acid dha lower triglycerides however dha alone appears raise lowdensity lipoprotein variant drives atherosclerosis sometimes inaccuratelyaccording called bad cholesterol ldlc values typically calculated estimate measured labs persons blood sample technical cost reasons however accurately calculated less common nmr lipid panel lab whilst eicosapentaenoic acid epa alone instead lowers parameters fishoil based drugs market similar uses mechanisms many fish oil dietary supplements evidence suggests marine based dietary supplements able reduce cardiovascular premature although effects may carry populations people ingredients dietary supplements carefully controlled prescription products fixed tested clinical trials prescription drugs prescription forms concentrated requiring fewer capsules taken increasing likelihood special caution taken people fish shellfish addition fatty acids taking ethyl eicosapentaenoic acid eepa puts people anticoagulants risk prolonged bleeding commonly reported side effect clinical trials joint pain people also reported pain mouth eepa tested pregnant excreted breast milk effects infants ingestion ethyl eicosapentaenoic acid eepa metabolized eicosapentaenoic acid epa epa absorbed small intestine enters circulation peak plasma concentration occurs five hours ingestion halflife hours epa lipolyzed mostly eicosapentaenoic acid epa active metabolite ethyl eicosapentaenoic acid eepa like fatty acid based drugs appears reduce production triglycerides liver enhance clearance triglycerides circulating lowdensity lipoprotein vldl particles way clear potential mechanisms include increased breakdown fatty acids inhibition diglyceride acyltransferase involved biosynthesis triglycerides liver increased activity lipoprotein lipase ethyl eicosapentaenoic acid eepa ethyl ester eicosapentaenoic acid fatty july us food drug administration fda approved ethyl eicosapentaenoic acid eepa severe hypertriglyceridemia adjunct dietary amarin corporation developed amarin corporation challenged fdas authority limit ability market drug offlabel use case appeal changing way fda regulates marketing ethyl eicosapentaenoic acid eepa second fishoil drug approved ethyl esters glaxosmithklines lovaza approved initial sales robust amarin hoped labels two drugs similar doctors prescribed lovaza people triglycerides lower mgdl based clinical evidence amarin wanted actively market eepa population well would greatly expanded revenue applied fda permission fda response may amarin sued fda infringing first amendment august judge ruled fda could prohibit truthful promotion drug unapproved uses would violate protection free ruling left open question fda would allow amarin say eepa march fda amarin agreed amarin would submit specific marketing material fda fda review usual prescription medications parties disagreed whether material truthful would seek judge december fda approved use icosapent ethyl adjunctive secondary therapy reduce risk cardiovascular events among adults elevated triglyceride levels type fat blood milligrams per deciliter people must also either established cardiovascular disease alone diabetes along two additional risk factors cardiovascular icosapent ethyl first fda approved drug reduce cardiovascular risk among people elevated triglyceride levels addon maximally tolerated statin efficacy safety icosapent ethyl established study participants either years older documented history coronary artery cerebrovascular carotid artery peripheral artery disease years older diabetes additional risk factors cardiovascular participants received icosapent ethyl significantly less likely experience cardiovascular event stroke heart clinical trials icosapent ethyl associated increased risk atrial fibrillation atrial flutter irregular heart rhythms requiring incidence atrial fibrillation greater among participants history atrial fibrillation atrial icosapent ethyl also associated increased risk bleeding incidence bleeding higher among participants also taking medications increase risk bleeding aspirin clopidogrel warfarin january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product vazkepa intended reduce risk cardiovascular events people high cardiovascular applicant medicinal product amarin pharmaceuticals ireland approved medical use european union march httpsenwikipediaorgwikiethyleicosapentaenoicacid